Dual antiplatelet therapy (DAPT) with aspirin and a P2Y~12~ inhibitor is the cornerstone of treatment for the prevention of thrombotic events in patients undergoing percutaneous coronary intervention (PCI) ([@bib1]). Although clopidogrel is the most commonly used P2Y~12~ inhibitor, its pharmacodynamic (PD) effects are nonuniform, and patients with high on-treatment platelet reactivity (HPR) are at increased thrombotic risk ([@bib2], [@bib3], [@bib4], [@bib5], [@bib6]). Such PD variability is in part attributed to genetic polymorphisms of the cytochrome P450 (CYP) 2C19 enzyme, a key modulator of clopidogrel metabolism ([@bib7], [@bib8], [@bib9], [@bib10]). In particular, carriers of loss-of-function (LOF) alleles of the *CYP2C19* gene are associated with reduced generation of clopidogrel's active metabolite, diminished platelet inhibition, and increased rates of thrombotic events ([@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]). Consequently, drug-regulating authorities have issued a boxed warning on the reduced efficacy of clopidogrel among *CYP2C19* LOF carriers and suggest that alternative P2Y~12~-inhibiting therapies (i.e., prasugrel or ticagrelor) be used in these individuals ([@bib14],[@bib15]). However, in clinical practice, implementing a strategy of genotype-guided selection of oral P2Y~12~ inhibitor has been limited by turnaround times of test results ([@bib16], [@bib17], [@bib18]).

Prasugrel and ticagrelor are characterized by more potent platelet inhibitory effects and greater efficacy in reducing thrombotic complications, albeit at the expense of increased bleeding, compared with clopidogrel ([@bib19], [@bib20], [@bib21]). Post hoc analyses of large-scale investigations have not shown any interaction between *CYP2C19* LOF polymorphisms and the clinical effects of prasugrel and ticagrelor ([@bib22], [@bib23], [@bib24], [@bib25]). However, prasugrel and ticagrelor differ considerably regarding their pharmacokinetic properties, and studies assessing the comparative PD effects between prasugrel and ticagrelor have yielded conflicting findings, with earlier investigations suggesting ticagrelor to have enhanced and less variable P2Y~12~ inhibitory effects with lower rates of HPR compared with prasugrel ([@bib19],[@bib26]). Of note, although ticagrelor is a direct-acting P2Y~12~ inhibitor, prasugrel is a prodrug that needs to be metabolized by CYP enzymes to generate an active metabolite to exert its effects ([@bib19]). Hence, it had been suggested that genetic polymorphisms regulating CYP enzyme activity could have contributed to these findings ([@bib26]). Although subsequent studies have failed to demonstrate greater P2Y~12~ inhibitory effects of ticagrelor over prasugrel, or for these effects to be potentially modulated by CYP2C19 genetic status ([@bib19],[@bib22],[@bib23],[@bib27]), to date there are no studies that have prospectively compared these agents specifically among *CYP2C19* LOF carriers.

The aim of this investigation was to assess the feasibility of implementing a rapid bedside *CYP2C19* genetic testing assay in real-world clinical practice of patients undergoing coronary angiography and to compare the PD effects of prasugrel and ticagrelor selectively among those identified as having a *CYP2C19* LOF allele and undergoing PCI.

Methods {#sec1}
=======

Study design and participants {#sec1.1}
-----------------------------

This was a prospective, randomized, parallel design, open-label investigation conducted in patients scheduled to undergo diagnostic coronary angiography with intent to undergo ad hoc PCI (Clinicaltrials.gov identifier: [NCT02065479](https://clinicaltrials.gov/ct2/show/NCT02065479){#intref0015}). The study was performed at the University of Florida Health--Jacksonville (Jacksonville, Florida). Patients were screened the same day of the scheduled procedure and before going to the interventional suite. Specific study inclusion and exclusion criteria are provided in the [Supplemental Appendix](#appsec1){ref-type="sec"}. In brief, patients age 18 to 75 years scheduled for diagnostic coronary angiography with intent to undergo ad hoc PCI and who did not have any contraindications to treatment with prasugrel or ticagrelor were considered for CYP2C19 genetic testing. Patients could have been on aspirin monotherapy (81 mg every day) or on DAPT with aspirin (81 mg every day) and clopidogrel (75 mg every day); patients who were not on any antiplatelet medication were treated with aspirin 325 mg the morning of the procedure. Patients with stable ischemic heart disease and patients with non--ST-segment elevation acute coronary syndrome (ACS) were eligible. Only patients undergoing urgent/emergent coronary angiography that would not allow for genetic testing results to be available at the time of PCI were excluded (e.g., patients undergoing primary PCI, cardiogenic shock). Patients meeting study entry criteria underwent rapid genetic testing using the Spartan RX assay (Spartan Bioscience, Ottawa, Ontario, Canada). The Spartan RX assay identifies the following *CYP2C19* alleles: ∗1, ∗2, ∗3, and ∗17. The most common LOF alleles are ∗2 and ∗3. Therefore, carriers of ∗2 or ∗3 LOF carrier status (homozygotes \[∗2/∗2, ∗3/∗3, or ∗2/∗3\] or heterozygotes \[∗1/∗2, ∗1/∗3, ∗2/∗17, ∗3/∗17\]) were considered eligible for randomization if they proceeded with PCI. Patients who were noncarriers of LOF alleles (∗1/∗1, ∗1/∗17, or ∗17/∗17) were not eligible for randomization and considered as screen failures and treated per standard of care; similarly, patients with *CYP2C19* LOF alleles who did not undergo PCI were considered as screen failures and treated per standard of care.

Patients identified to be *CYP2C19* LOF allele carriers and undergoing PCI were randomly assigned 1:1 using a computer-based randomization system to either prasugrel (60 mg loading dose to 10 mg daily maintenance dose) or ticagrelor (180 mg loading dose to 90 mg twice a day maintenance dose). Randomization was stratified according to baseline antiplatelet therapy (aspirin alone vs. DAPT with aspirin and clopidogrel). Loading dose administration was given immediately after PCI as per local standard of care. Randomized patients underwent PD testing at 5 time points: 1) baseline (before initiating the PCI procedure and loading dose administration of antiplatelet therapy); 2) 30 mi after loading dose administration; 3) 2 h after loading dose administration; 4) 24 h after loading dose administration or at hospital discharge (whichever came first); 5) during routine clinical follow-up 1 to 4 weeks after PCI while on maintenance dose antiplatelet therapy. At 24 h and at follow-up, blood was collected before the morning dose of prasugrel or ticagrelor to measure trough levels of platelet inhibition. Laboratory personnel were blinded to treatment assignments. Compliance to randomized treatment was assessed by pill count and patient interview. After completing the study, the choice and length of DAPT were left at the discretion of the treating cardiologist. The study complied with the Declaration of Helsinki, was approved by the University of Florida Institutional Review Board, and all patients gave their written informed consent. A flow diagram of the study design is illustrated in [Figure 1](#fig1){ref-type="fig"}.Figure 1Study Designbid = twice a day; LD = loading dose; LHC = left heart catheterization; LOF = loss of function; MD = maintenance dose; PCI = percutaneous coronary intervention; PD = pharmacodynamics; qd = every day.

Genetic and PD testing {#sec1.2}
----------------------

### Spartan RX rapid genotyping {#sec1.2.1}

Spartan RX (Spartan Bioscience Inc.) defines CYP2C19 (∗1, ∗2, ∗3, ∗17) allele status within 1 h. This test consists of 4 separate steps intended to be done in \<8 min: acquisition of a buccal swab; insertion of the swab into the cartridge; insertion of the reaction solution into the device; and analysis of *CYP2C19* genotype triggered by a button on the device. In this study, patients with the ∗2 or ∗3 LOF carrier status (homozygotes \[∗2/∗2, ∗3/∗3, or ∗2/∗3\] or heterozygotes \[∗1/∗2, ∗1/∗3, ∗2/∗17, ∗3/∗17\]) were considered eligible for randomization, whereas noncarriers of LOF alleles (∗1/∗1, ∗1/∗17, or ∗17/∗17) were not ([@bib28], [@bib29], [@bib30]).

### VerifyNow point-of-care testing {#sec1.2.2}

The VerifyNow System is a turbidimetric-based optical detection system that measures platelet-induced aggregation as an increase in light transmittance (Accriva, San Diego, California), and was used according to the manufacturer's instructions ([@bib29]). The assay is based on microbead agglutination and uses specific reagents for the pathways of interest. The instrument measures this change in optical signal and reports results in P2Y~12~ reaction units (PRUs). HPR was defined by PRU \>208 ([@bib31]).

Study endpoints and determination of sample size {#sec1.3}
------------------------------------------------

The primary endpoint of the study was the noninferiority in platelet reactivity, measured as PRU, at 24 h or hospital discharge (whichever came first) of prasugrel versus ticagrelor among LOF allele carriers. Under the assumption of 0 difference in mean PRU between treatments and a common standard deviation of 50 PRU, a sample size of 60 patients with valid data would allow for the 95% confidence interval (CI) to stay within 40 PRU with an 85% power and alpha = 0.025 ([@bib27],[@bib32]). Considering up to a 25% rate of invalid results due to hemolysis or drop-out, we planned to randomize up to a total of 80 patients to ensure complete data for analysis. Noninferiority was assessed using a 95% CI of the difference in mean PRU between the 2 groups. The 40 PRU noninferiority margin was defined according to previously published studies ([@bib33]). Exploratory endpoints included assessment of PD differences between prasugrel and ticagrelor at 30 min, 2 h, and 1 to 4 weeks, and rates of HPR at all study time points.

Statistical analysis {#sec1.4}
--------------------

Continuous variables are expressed as a mean ± SD or median (interquartile range) as appropriate. Categorical variables are expressed as frequencies and percentages. Comparisons between continuous variables was performed using Student's *t*-test or Wilcoxon rank-sum test. Comparisons between categorical variables were performed using chi-square test or Fisher exact test. Missing data were not imputed. An analysis of variance method with a general linear model, with treatment as the main effect, was used to evaluate the primary noninferiority endpoint as well as all superiority between-group comparisons at each time point. Least squares mean differences in PRU between groups and the corresponding 2-sided 95% CI for the difference was obtained based on the analysis of variance model and used to assess noninferiority. The p values are used to report superiority testing, and a 2-tailed p value of \<0.05 is considered to indicate a statistically significant difference for all the analyses performed. The PD population included all patients with PD data and without a major protocol deviation thought to significantly affect the effects of ticagrelor or prasugrel. The PD population was used for analysis of all primary and exploratory PD variables. Statistical analysis was performed by our group using SPSS v24.0 software (SPSS Inc., Chicago, Illinois).

Results {#sec2}
=======

Between March 2014 and September 2018, a total of 781 consecutive patients scheduled for left heart catheterization with the intent to undergo PCI were genotyped. Of these, 222 (28.5%) patients were carriers of at least 1 LOF: 9% were homozygotes (∗2/∗2, n = 20) and 91% were heterozygotes (∗1/∗2, n = 189; ∗1/∗3, n = 1; ∗2/∗17, n = 32). Of the cohort of *CYP2C19* LOF carriers, 157 patients did not meet criteria to be randomized. Thus, a total 65 patients underwent PCI and were randomized to either prasugrel (n = 32) or ticagrelor (n = 33). These patients represented the PD population of the study ([Figure 2](#fig2){ref-type="fig"}). Baseline characteristics of the PD population are summarized in [Table 1](#tbl1){ref-type="table"}. *CYP2C19* LOF carriers who were not randomized were more likely to be female and less likely to have ACS compared with those who were randomized ([Supplemental Table 1](#appsec1){ref-type="sec"}).Figure 2Trial ProfileCABG = coronary artery bypass graft; CAD = coronary artery disease; CYP = cytochrome P450; GPI = glycoprotein IIb/IIIa inhibitor; LOF = loss of function; PCI = percutaneous coronary intervention.Table 1Baseline Characteristics of the PD PopulationPrasugrel (n = 32)Ticagrelor (n = 33)p ValueAge, yrs60 ± 958 ± 80.593Gender, male25 (78)26 (79)1.000BMI, kg/m^2^31 ± 531 ± 50.986Race0.690 White21 (66)23 (70) Black9 (28)8 (24) Other2 (6)2 (6)Genotype0.398 ∗1/∗224 (75)27 (82) ∗1/∗30 (0)1 (3) ∗2∗/174 (12.5)1 (3.0) ∗2/∗24 (12.5)4 (12.0)ACS17 (53)18 (54)1.000SIHD15 (47)15 (46)Cohort1.000 Aspirin25 (78)26 (79) DAPT7 (22)7 (21)Hypertension28 (87)29 (88)1.000Dyslipidemia20 (62)24 (73)0.434Active smoking11 (34)9 (27)0.599Diabetes mellitus14 (44)10 (30)0.310Prior MI10 (31)5 (15)0.150Prior PCI11 (34)15 (45)0.450Prior CABG7 (22)8 (24)1.000Creatinine, mg/dl1.0 ± 0.30.9 ± 0.20.373Platelet count, × 10^3^/μl232 ± 70213 ± 450.206Hematocrit, %41 ± 542 ± 30.182Medications[∗](#tbl1fnlowast){ref-type="table-fn"} Insulin therapy6 (19)5 (15)0.751 OAD8 (25)9 (27)0.358 Beta-blockers14 (44)20 (61)0.218 ACE-I/ARB16 (50)19 (58)0.622 Statins20 (62.5)25 (76)0.290[^1][^2][^3]

In the PD population, 8 patients (12%) were homozygotes for ∗2/∗2, and 57 (88%) were heterozygotes (∗1/∗2: 78.5%; ∗1/∗3: 1.5%; ∗2/∗17: 8%). Fifty-one (78.5%) and 14 (21.5%) patients were on aspirin or DAPT before randomization, respectively. No ischemic or Bleeding Academic Research Consortium type 2 to 5 bleeding events were observed; 3 patients (9%) receiving ticagrelor experienced dyspnea, which led to drug discontinuation in 1 patient, versus none of those receiving prasugrel; 1 patient receiving prasugrel had a stroke; 2 patients had chest pain during follow-up that did not require any intervention (prasugrel, n = 1; ticagrelor, n = 1).

Pharmacodynamic results {#sec2.1}
-----------------------

At baseline, PRU levels were similar between groups. A significant reduction in PRU was observed as early as 30 min following loading dose for both prasugrel (p = 0.018) and ticagrelor (p = 0.029). PRU levels continued to markedly reduce to a similar extent with no differences between groups at 2 h and 24 h (or hospital discharge) after loading dose administrations and remained low at follow-up while on maintenance therapy ([Figure 3](#fig3){ref-type="fig"}). Median time between study drug loading dose and primary end point sample was 20 h (interquartile range: 7 to 22 h). Mean PRU levels at this time point were 33 ± 56 for prasugrel versus 36 ± 41 for ticagrelor (mean difference = −3; 95% CI: −28 to 22; p = 0.814 for superiority) meeting the primary endpoint of noninferiority. HPR rates also significantly reduced over time, with no differences between groups at any time point ([Figure 4](#fig4){ref-type="fig"}). Results were consistent irrespective of baseline antiplatelet treatment regimen (aspirin monotherapy or DAPT; [Supplemental Figure 1](#appsec1){ref-type="sec"}), with no cohort by treatment group interaction (p for interaction \>0.05 for all time points)Figure 3Pharmacodynamic Assessment Measured by VerifyNow P2Y12 After Administration of Prasugrel Versus TicagrelorThe main figure represents P2Y~12~ reaction units (PRUs) measured by the VerifyNow P2Y12 assay. Values are expressed as means. **Error bars** indicate SDs; p values indicate the comparisons for superiority between groups at each time point. The **box** represents the primary endpoint: 24-h PRU absolute difference and 2-sided 95% confidence interval between prasugrel and ticagrelor. **Tinted area** indicates zone of noninferiority (NI). The **dotted line** represents the prespecified limit of noninferiority of +40.Figure 4Individual Values of Platelet Reactivity Measured by VerifyNow P2Y12 After Administration of Prasugrel Versus TicagrelorComparisons of P2Y~12~ reaction units (PRUs) measured by the VerifyNow P2Y12 assay. Data are presented as individual values. The **dashed line** indicates threshold for high on-treatment platelet reactivity. **Solid lineswith error bars** indicate mean ± SD. HPR = high on-treatment platelet reactivity.

Discussion {#sec3}
==========

The implementation of genotype-guided selection of P2Y~12~-inhibiting therapy in patients undergoing PCI has been limited in real-world clinical practice by the availability of assays able to provide results of CYP2C19 genotypes in a timely fashion ([@bib16], [@bib17], [@bib18]). Patients most commonly undergo ad hoc PCI immediately following diagnostic angiography, which further emphasizes the importance of having readily available genotyping results. Earlier small-scale investigations have suggested the clinical utility of genotype-guided selection of oral P2Y~12~ inhibitors in patients undergoing PCI ([@bib34], [@bib35], [@bib36], [@bib37]). However, some of these were conducted using genotyping approaches that would require several days, making results unavailable until after hospital discharge ([@bib34],[@bib35]). This has important implications. First, switching antiplatelet treatment after hospital discharge is of limited practicality; second, the early post-PCI period is when the risk for thrombotic complication is highest, underscoring the importance of optimized antiplatelet therapy during this time frame; third, adherence is improved when medications are prescribed before hospital discharge ([@bib38],[@bib39]). The results of our investigation overcome these limitations and support the feasibility of using a rapid *CYP2C19* genotyping assay among both patients with stable coronary syndrome and patients with ACS undergoing diagnostic coronary angiography, with intent to undergo ad hoc PCI, in real-world clinical practice. In particular, such rapid bedside genetic testing assay allowed for very rapid turnaround times of results, with patients approached the same day of their procedure and availability of *CYP2C19* genotypes within 1 h and before patients undergo PCI. This in contrast to other studies assessing the feasibility of rapid bedside genetic testing, in which results were not available before the start of the PCI procedure ([@bib29],[@bib30],[@bib40]). Therefore, similar to other standard laboratory tests (e.g., complete blood count, creatinine, liver function, coagulation panel) performed in these patients, in our study, genotyping results were readily available when the decision on choice of oral P2Y~12~-inhibiting therapy most commonly occurs (i.e., at the time of PCI).

The use of platelet function or genetic testing to tailor the selection of P2Y~12~-inhibiting therapy as a strategy to improve outcomes has been a subject of investigation for more than a decade ([@bib31]). Although earlier studies of platelet function testing, mostly evaluating a strategy of escalation of P2Y~12~-inhibiting therapy, have failed to show any clinical benefit, the TROPICAL ACS (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes) trial demonstrated that a strategy of platelet function guided de-escalation was noninferior to maintaining conventional nonguided treatment at 12 months in patients with high-risk ACS undergoing PCI ([@bib41]). The results of this study led an update in revascularization guidelines that now indicate that platelet function testing can be considered to help guide the decision on choice of antiplatelet therapy in patients with ACS who cannot take the more potent P2Y~12~ inhibitors ([@bib42]). However, there are some limitations associated with platelet function guided de-escalation. First, following de-escalation, clopidogrel maintenance therapy needs to be maintained for a certain period for it to achieve its full antiplatelet effects before performing platelet function testing to assess responsiveness, and if patients have inadequate platelet inhibition they would need to be switched back to a more potent P2Y~12~ inhibitor; second, patients with inadequate response to clopidogrel during this time frame are exposed to an increased risk of thrombotic complications ([@bib43]). The presence of inadequate clopidogrel response can be further exacerbated by a drug-drug interaction that may occur with de-escalation from ticagrelor to clopidogrel ([@bib33]). Indeed, using a genotype-guided approach overcomes these shortcomings, as also endorsed by expert consensus recommendations ([@bib31]). Importantly, the clinical impact of a genotype-guide de-escalation approach was recently demonstrated in the POPular Genetics (Patient Outcome after primary PCI Genetics) study ([@bib40]). In particular, this study was the first adequately powered randomized study of a *CYP2C19* genotype-guided strategy for selection of oral P2Y~12~ inhibitor (LOF carriers received ticagrelor or prasugrel and noncarriers received clopidogrel) and showed this strategy to be noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of major or minor bleeding events among patients with ST elevation myocardial infarction undergoing primary PCI ([@bib40]). Indeed, it may be argued that this and other studies support the feasibility of performing rapid bedside genotyping; however, none of these executed the test routinely before undergoing diagnostic coronary angiography enabling in-laboratory guidance of P2Y~12~-inhibiting therapy in patients requiring PCI ([@bib29],[@bib30],[@bib40]).

Although prior investigations have assessed the comparative PD effects of prasugrel and ticagrelor, yielding conflicting findings ([@bib26],[@bib27]), this is the first study to assess this specifically among *CYP2C19* LOF carriers. We observed no differences in platelet reactivity between prasugrel and ticagrelor among *CYP2C19* LOF carriers undergoing PCI during the entire study time-course assessing the effects of both the loading and maintenance doses of these agents. Although CYP enzymes are involved in prasugrel metabolism, which could potentially affect its PD effects, the contribution of *CYP2C19* is minimal, as also supported by the very high levels of platelet inhibition achieved with prasugrel in our study ([@bib44]). Moreover, our investigation confirms results of prior studies on the prompt and enhanced platelet inhibitory effects associated with escalation from clopidogrel to prasugrel or ticagrelor, leading to a reduction in HPR rates when a loading dose is used ([@bib27],[@bib38]).

In addition to the POPular Genetics study, in which ticagrelor was the most commonly used potent P2Y~12~ inhibitor among patients who were *CYP2C19* LOF carriers, our study observations also have important clinical implications in light of the recently reported ISAR REACT 5 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5) study ([@bib45]). ISAR REACT 5 had hypothesized that ticagrelor would reduce ischemic events to a greater extent than prasugrel in patients with ACS undergoing invasive management in part based on the assumption of the enhanced antiplatelet effects of ticagrelor ([@bib45]). However, ISAR REACT 5 failed to demonstrate its study hypothesis and actually showed significantly reduced ischemic events with prasugrel over ticagrelor at 12 months without differences in bleeding. A number of reasons have been provided to explain such study findings, including compliance issues (once-daily administration of prasugrel vs. twice-daily with ticagrelor), increased rate of nonbleeding side effects with ticagrelor (i.e., dyspnea) leading to drug discontinuation, and differential pharmacologic profile (short half-life, reversibility of action, and drug interactions with ticagrelor). Our current investigation, showing no differences in PD effects between prasugrel and ticagrelor among *CYP2C19* LOF carriers, is in line with prior investigations from our group assessing the comparative PD effects between these agents not stratified according to CYP2C19 genotype ([@bib27]). Overall, these observations may have practical and cost implications, given that prasugrel is now available in a generic formulation in many countries, making it an attractive treatment option, including among physicians who elect an alternative agent to clopidogrel based on results of genetic testing.

Study limitations {#sec3.1}
-----------------

This study was not designed to assess the clinical outcomes of a genotype-guided strategy in patients undergoing PCI, which is the objective of a number of ongoing investigations ([@bib23], [@bib24], [@bib25]). Moreover, it was not designed to compare the safety and efficacy of prasugrel versus ticagrelor. Our study used only the VerifyNow assay for PD assessments. However, the choice to use only this rapid bedside assay was in line with the overall scope of this investigation to consider tests, both PD and genetic, of simple and practical utility, as well as fast turnaround. Ultimately, there are more genetic polymorphisms of *CYP2C19* than those assessed by the Spartan RX assay. However, their prevalence is extremely rare and of unclear clinical significance ([@bib31]).

Conclusions {#sec4}
===========

Rapid *CYP2C19* genotyping using the Spartan assay is feasible in providing results in a timely fashion in a real-world clinical practice of patients undergoing coronary angiography. Among patients with *CYP2C19* LOF carrier status undergoing ad hoc PCI in this setting, prasugrel and ticagrelor markedly reduce levels of platelet reactivity to a similar extent with no differences between groups. Ongoing large-scale clinical investigations will help define the safety and efficacy of using genetic testing to individualize the choice of oral P2Y~12~-inhibiting therapy in patients undergoing PCI.Perspectives**COMPETENCY IN MEDICAL KNOWLEDGE:** The implementation of genotype-guided selection of P2Y~12~-inhibiting therapy in patients undergoing PCI has been limited in real-world clinical practice by the availability of assays able to provide results of CYP2C19 genotypes in a timely fashion. The results of our investigation overcome these limitations and support the feasibility of using a rapid genotyping assay among both patients with stable coronary syndrome and patients with ACS undergoing diagnostic coronary angiography, with intent to undergo ad hoc PCI, in real-world clinical practice. In our study, genotyping results were readily available when the decision on choice of oral P2Y~12~-inhibiting therapy most commonly occurs (i.e., at the time of PCI). The potential clinical benefits of a genotype-guided approach have been recently demonstrated. However, none of these performed the test routinely before undergoing diagnostic coronary angiography, enabling in-laboratory guidance of P2Y~12~-inhibiting therapy in patients requiring PCI. Although CYP enzymes are involved in prasugrel metabolism, which could potentially affect its PD effects, our study showed no differences in platelet reactivity between prasugrel and ticagrelor among *CYP2C19* LOF carriers undergoing PCI during the entire study time-course, assessing the effects of both the loading and maintenance doses of these agents. These observations may have practical and cost implications, given that prasugrel is now available in a generic formulation in many countries, making it an attractive treatment option, including among physicians who elect an alternative agent to clopidogrel based on results of genetic testing.**TRANSLATIONAL OUTLOOK:** Our current investigation demonstrating no differences in PD effects between prasugrel and ticagrelor in this subset of patients, which is in line with prior investigations from our group assessing the comparative PD effects between these agents not stratified according to CYP2C19 genotype, support that recent trial findings showing significantly reduced ischemic events with prasugrel over ticagrelor cannot be attributed to differential levels of P2Y~12~ inhibition. However, our study was not designed to assess the clinical outcomes of a rapid genotype-guided strategy in patients undergoing PCI. Moreover, it was not designed to compare the safety and efficacy of prasugrel versus ticagrelor in CYP2C19 LOF carriers, which would also warrant further investigation in large-scale clinical trials.
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[^1]: Values are mean ± SD and or n (%).

[^2]: ACE-I = angiotensin converting enzyme inhibitor; ACS = acute coronary syndrome; ARB = angiotensin receptor blocker; BMI = body mass index; CABG = coronary artery bypass graft; DAPT = dual antiplatelet therapy; MI = myocardial infarction; OAD = oral antidiabetic drugs; PD = pharmacodynamics; PCI = percutaneous coronary intervention; SIHD = stable ischemic heart disease.

[^3]: Medications at the time of coronary angiography.
